CN113164764B - 葡萄糖敏感性胰岛素及其用途 - Google Patents

葡萄糖敏感性胰岛素及其用途

Info

Publication number
CN113164764B
CN113164764B CN201980061402.3A CN201980061402A CN113164764B CN 113164764 B CN113164764 B CN 113164764B CN 201980061402 A CN201980061402 A CN 201980061402A CN 113164764 B CN113164764 B CN 113164764B
Authority
CN
China
Prior art keywords
human insulin
insulin
glucose
compound
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980061402.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113164764A (zh
Inventor
T·霍格-詹森
A·R·马德森
T·克鲁瑟
P·索尔伯格
A·默里
A·P·戴维斯
A·M·查普曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Oxford Research Center Co ltd
Zlo Ltd
Original Assignee
Novo Nordisk Oxford Research Center Co ltd
Zlo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Oxford Research Center Co ltd, Zlo Ltd filed Critical Novo Nordisk Oxford Research Center Co ltd
Publication of CN113164764A publication Critical patent/CN113164764A/zh
Application granted granted Critical
Publication of CN113164764B publication Critical patent/CN113164764B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980061402.3A 2018-09-19 2019-09-18 葡萄糖敏感性胰岛素及其用途 Active CN113164764B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18195490.0 2018-09-19
EP18195490 2018-09-19
EP19176911 2019-05-28
EP19176911.6 2019-05-28
PCT/EP2019/074987 WO2020058322A1 (en) 2018-09-19 2019-09-18 Glucose sensitive insulins and uses thereof

Publications (2)

Publication Number Publication Date
CN113164764A CN113164764A (zh) 2021-07-23
CN113164764B true CN113164764B (zh) 2025-07-29

Family

ID=67989013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980061402.3A Active CN113164764B (zh) 2018-09-19 2019-09-18 葡萄糖敏感性胰岛素及其用途

Country Status (5)

Country Link
US (1) US11541122B2 (https=)
EP (1) EP3852873A1 (https=)
JP (1) JP7439062B2 (https=)
CN (1) CN113164764B (https=)
WO (1) WO2020058322A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof
GB202201000D0 (en) 2022-01-26 2022-03-09 Carbometrics Ltd Saccharide sensing systems
CN117342985B (zh) * 2023-06-02 2025-06-20 山东新时代药业有限公司 一种仑伐替尼中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326472A1 (de) 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
JP2903077B2 (ja) 1990-09-11 1999-06-07 科学技術振興事業団 尿素誘導体及び尿素誘導体含有組成物並びに機能薄膜
US5180481A (en) 1992-03-24 1993-01-19 Clifton Carey Phosphate selective composition and electrode
NL1008789C2 (nl) 1998-04-02 1999-10-05 Stichting Tech Wetenschapp Anion-complexerende verbinding, werkwijze voor de bereiding ervan, een ionselectief membraan alsmede een sensor voorzien van een dergelijke verbinding of membraan.
KR20030004317A (ko) 1999-12-29 2003-01-14 노보 노르디스크 에이/에스 인슐린 선구물질 및 인슐린 선구물질 유사체의 제조 방법
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
US8569231B2 (en) * 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
GB201207392D0 (en) * 2012-04-27 2012-06-13 Univ Bristol Novel compounds
JP6914844B2 (ja) * 2015-03-13 2021-08-04 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ グルコース制御立体配座スイッチを含むインスリン類似体
WO2018167503A1 (en) 2017-03-15 2018-09-20 Ziylo Limited Macrocyclic compounds

Also Published As

Publication number Publication date
JP7439062B2 (ja) 2024-02-27
JP2022501364A (ja) 2022-01-06
WO2020058322A1 (en) 2020-03-26
EP3852873A1 (en) 2021-07-28
US11541122B2 (en) 2023-01-03
CN113164764A (zh) 2021-07-23
US20220047708A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
ES2461341T3 (es) Profármacos para análogos de hormona tiroidea
TWI792596B (zh) 新穎脂肪酸及其於共軛至生物分子之用途
KR20220025861A (ko) 항체 약물 복합체, 이의 중간체, 제조 방법 및 용도
CN113164764B (zh) 葡萄糖敏感性胰岛素及其用途
ES2435522T3 (es) Derivados de insulina
US20130137645A1 (en) Modified peptides and proteins
CN113646329B (zh) 葡萄糖敏感性胰岛素衍生物
BRPI0607248A2 (pt) conjugado de um polipeptìdeo e um oligossacarìdeo, composição farmacêutica, uso do conjugado, e, processo para a preparação de um conjugado
KR20060132543A (ko) 신규의 인슐린 유도체
CN114401731A (zh) 用于治疗人类免疫缺陷病毒的组合物及方法
CN101955527A (zh) 新型胰岛素衍生物
WO2024155750A1 (en) Lysosomal targeting bifunctional molecules for degradation of autoantibodies
WO2022126593A1 (zh) 一种靶向trop2的抗体药物偶联物、其制备方法及应用
CN114685646A (zh) 一种多肽侧链类似物的制备方法及其应用
CN120826239A (zh) 包含白蛋白结合部分的药物化合物
CZ20011152A3 (cs) Substituované 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanolové deriváty, způsob jejich přípravy, léčiva obsahující tyto sloučeniny a jejich použití
CN104587487B (zh) 一种应用于靶向给药系统的新的支链连接体
TW202540152A (zh) 具有經修飾之離胺酸殘基之雜合肽化合物
WO2022126569A1 (zh) 一种靶向b7-h3的抗体药物偶联物、其制备方法及应用
US20240408218A1 (en) Conjugates of glucagon and ampk activators
US9931379B2 (en) Oxyntomodulin analogs and methods of making and using same
WO2023144240A1 (en) Glucose sensitive insulin derivatives and uses thereof
WO2022116141A1 (zh) 抗体药物偶联物、其中间体、制备方法及应用
WO2015096725A1 (zh) 端基具有亲脂性结构的线性脂肽、其制备方法及用途
JP2021504402A (ja) 薬剤とグルコース感知タンパク質に結合し得る部分との新規のコンジュゲート

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Oxfordshire

Applicant after: Novo Nordisk Oxford Research Center Co.,Ltd.

Address before: West Sussex

Applicant before: ZLO Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment